Investigating cardiovascular health outcomes is critical, as weight loss may reduce long-term risks of hypertension, atherosclerosis, and insulin resistance
Additionally, it is most effective when combined with proper nutrition and lifestyle changes
The clinical team provides ongoing monitoring and protocol adjustments to ensure you achieve optimal results safely
Stop the plan and see your provider if you develop chest tightness, severe dizziness, swelling of the lips or face, or trouble breathing
Clinical evidence demonstrates tirzepatide produces average weight loss of 20-22% over 68 weeks in phase 3 trials, whereas glutathione's weight loss mechanism remains primarily indirect through oxidative stress reduction
The findings open the door to a possible dual-purpose role for these drugs in treating both systemic inflammation and cardiovascular comorbidity in RA